Novo Nordisk Showcases OASIS 4 Data Highlighting Broader Health Benefits of Oral Semaglutide 25 mg

Novo Nordisk unveiled new findings from its OASIS 4 Phase 3 trial at ObesityWeek® 2025 in Atlanta, reinforcing the potential of oral semaglutide 25 mg as a treatment option for adults with overweight and obesity. The company presented four abstracts that collectively expand the understanding of semaglutide’s impact beyond weight loss, revealing benefits for cardiometabolic health and overall well-being.

“Novo Nordisk has pioneered innovation in obesity treatment for 25 years, and the new OASIS 4 data reflect our ongoing commitment to improving the lives of people living with obesity,” said Martin Holst Lange, Chief Scientific Officer and Executive Vice President of Research & Development at Novo Nordisk. “These results extend clinical evidence for oral semaglutide beyond weight reduction to potential improvements in overall health.”

A cardiometabolic post hoc analysis from OASIS 4 evaluated how varying degrees of weight loss influenced blood sugar control and cardiovascular risk factors. Participants receiving oral semaglutide 25 mg once daily showed significant improvements in HbA1c, fasting glucose, insulin levels, and lipid profiles compared with placebo.

The study also revealed that 71.1% of participants with prediabetes achieved normal blood sugar levels after 64 weeks of treatment, versus 33.3% in the placebo group. Those who lost ≥15% of body weight experienced larger reductions in blood pressure, triglycerides, and C-reactive protein, key markers linked to cardiovascular health.

“As recently published in The New England Journal of Medicine, the OASIS 4 trial confirmed the strong weight-loss efficacy of oral semaglutide 25 mg,” said Dr. Domenica Rubino, Director of the Washington Center for Weight Management and Research. “These new findings show meaningful improvements in cardiometabolic outcomes — even among those who didn’t achieve the highest weight reductions.”

The new data strengthen Novo Nordisk’s case for oral semaglutide 25 mg as a comprehensive obesity treatment with measurable benefits in both weight and metabolic health.